Consistent with our findings in EC, elevated LMO3 expression has been associated with poor prognosis in gastric cancer [82] and neuroblastoma [83], PRKAA2 in endometrial cancer [84, 85] and RAB10 in breast cancer [86] and hepatocellular carcinoma [87]. Here, LMO3 is linked to endometrial cancer.